Analysts Say ‘Buy the Dip’ in These 3 Stocks

In This Article:

Smart stock investing shouldn’t be emotional, but investors are only human, after all, making it difficult to follow a rational trading strategy.

Investors should remember the advice of Warren Buffett: “We simply attempt to be fearful when others are greedy and to be greedy only when others are fearful.” What Buffett is advocating is the oldest of market advice: buy low and sell high.

Taking this into consideration, we set out on our own search for compelling investment opportunities trading at a discount. Using TipRanks database, we were able to find 3 stocks that are down from their recent peaks, while some Wall Street analysts are recommending to ‘buy the dip.’ Let's take a closer look.

Teladoc Health (TDOC)

We'll start with Teladoc, a remote medical care service, which makes use of online networking to connect patients with doctors for non-emergency matters, including ear-nose-throat issues, lab referrals, basic medical advice and diagnoses, and prescription refills for non-addictive medications. In the company’s words, it’s “remote house calls by primary care doctors,” using digital technology to offer an old-fashioned service.

Teladoc’s service is in high demand, and the corona year saw the company thrive – its business model was a perfect fit for COVID-19 pandemic conditions. Full-year revenues in 2020 grew 98% year-over-year, to 1.09 billion, and total patient visits increased by 156%, to 10.6 million. In addition, the company in October completed its merger with competitor Livongo, in a deal worth $18.5 billion. Teladoc shareholders now control 58% of the combined company.

While the move adds to Teladoc’s capabilities and potential patient base, it also meant the company incurred large costs during Q4. Teladoc had to pay up in cash for the merger, and as a result, the Q4 earnings results showed a heavy EPS loss of $3.07 per share.

In addition to the Q4 net loss, investors are also worried by the 2021 membership guidance. Specifically, the figure is likely to be between 52 million and 54 million, which implies growth of +3.4-7.4% year-over-year. This is way down from +40% in 2020 and +61% in 2019.

The stock has slipped 37% since its recent peak in mid-February, but Canaccord's 5-star analyst Richard Close says to 'buy this dip.'

“Bright spots such as multi-product sales, increasing utilization, new registration strength, and visit growth in noninfectious areas trump the membership metric when all is said and done. Opportunities have presented themselves in the past to jump into (or accumulate shares of) Teladoc -- we believe this is one of the opportunities,” Close confidently noted.